Merck & Co., Inc. Restructuring and Related Cost, Cost Incurred to Date
Merck & Co., Inc. (MRK) had Restructuring and Related Cost, Cost Incurred to Date of $3.90 billion as of 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2023-11-03
- 2023-09-30: Restructuring and Related Cost, Cost Incurred to Date $3.90B.
- 2023-06-30: Restructuring and Related Cost, Cost Incurred to Date $3.70B.
- 2023-03-31: Restructuring and Related Cost, Cost Incurred to Date $3.40B.
- 2022-12-31: Restructuring and Related Cost, Cost Incurred to Date $3.30B.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2023-09-30 | $3.90B 10-Q · filed 2023-11-03 |
| 2023-06-30 | $3.70B 10-Q · filed 2023-08-07 |
| 2023-03-31 | $3.40B 10-Q · filed 2023-05-05 |
| 2022-12-31 | $3.30B 10-K · filed 2023-02-24 |
| 2022-09-30 | $3.20B 10-Q · filed 2022-11-03 |
| 2022-06-30 | $3.00B 10-Q · filed 2022-08-05 |
| 2022-03-31 | $2.80B 10-Q · filed 2022-05-05 |
| 2021-12-31 | $2.70B 10-K · filed 2022-02-25 |
| 2021-09-30 | $2.40B 10-Q · filed 2021-11-05 |
| 2021-06-30 | $2.30B 10-Q · filed 2021-08-09 |
| 2021-03-31 | $2.10B 10-Q · filed 2021-05-05 |
| 2020-12-31 | $1.80B 10-K · filed 2021-02-25 |
| 2020-09-30 | $1.40B 10-Q · filed 2020-11-05 |
| 2020-06-30 | $1.20B 10-Q · filed 2020-08-05 |
| 2020-03-31 | $1.10B 10-Q · filed 2020-05-06 |
| 2018-12-31 | $14.10B 10-K · filed 2019-02-27 |
| 2018-09-30 | $14.00B 10-Q · filed 2018-11-06 |
| 2018-06-30 | $13.80B 10-Q · filed 2018-08-07 |
| 2018-03-31 | $13.60B 10-Q · filed 2018-05-08 |
| 2017-12-31 | $13.50B 10-K · filed 2018-02-27 |
| 2017-09-30 | $13.20B 10-Q · filed 2017-11-07 |
| 2017-06-30 | $13.00B 10-Q · filed 2017-08-08 |
| 2017-03-31 | $12.80B 10-Q · filed 2017-05-09 |
| 2016-12-31 | $12.60B 10-K · filed 2017-02-28 |
| 2016-09-30 | $12.20B 10-Q · filed 2016-11-07 |
| 2016-06-30 | $12.00B 10-Q · filed 2016-08-08 |
| 2016-03-31 | $11.70B 10-Q · filed 2016-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |